Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti- remodelling agent.
申请公布号
WO2015186037(A1)
申请公布日期
2015.12.10
申请号
WO2015IB54082
申请日期
2015.05.29
申请人
NOVARTIS AG;ROWLANDS, MARIANNA;TESSIER, CLEMENCE ANNE JEANNE MARIE;WHITTAKER, PAUL ANDREW
发明人
ROWLANDS, MARIANNA;TESSIER, CLEMENCE ANNE JEANNE MARIE;WHITTAKER, PAUL ANDREW